Federal authorities are accusing the two top officials of CANARX, a Canadian prescription drug company, of running a long-running scheme to illegally import prescription drugs into the United States, according to court records filed Tuesday.
John Thomas Howard, the company's treasurer and a director, was arrested Sunday on smuggling and conspiracy charges, according to the records. The arrest warrant also charges him with introducing misbranded drugs into interstate commerce and illegal drug importation. No plea has been filed.
His brother, Bob Howard, is president and a director of CANARX. He is also wanted in the investigation and has not yet been taken into custody, according to an affidavit from Dustin Dobbs, a special agent with the Food and Drug Administration's Office of Criminal Investigations.
The affidavit states that the FDA found "there is probable cause to believe that (CANARX) illegally imported or caused the illegal importation of prescription drugs into the United States." It does not specify which medications were involved. The criminal complaint covers February 22, 2017, through April 15, 2026.
The company's general counsel, Joseph Morris, said in a statement to CNBC: "The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court."
The FDA has scrutinized the company for several years. The agency seized medication CANARX was shipping in 2023, which it said was potentially misbranded and counterfeit. In 2019, it sent the company a warning letter. Morris responded that CANARX was not misleading patients, but agreed to stop importing drugs that must be administered by a doctor.
Gilead Sciences separately has a pending civil lawsuit accusing CANARX and other companies of illegally importing Biktarvy, its HIV medication. CANARX has not responded to that lawsuit. A Gilead spokesperson said the company "welcome[s] the government's efforts to hold accountable those whose conduct may put patients at risk."